Primary Care Diabetes
Volume 4, Issue 2 , Pages 113-117 , July 2010

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

  • Kjeld Hermansen

      Affiliations

    • Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 89 49 76 51; fax: +45 89 49 76 59.
    • ,
  • Ronette L. Kolotkin

      Affiliations

    • Obesity and Quality of Life Consulting, PLLC, Durham, NC, USA
    • Department of Community and Family Medicine, Duke University Medical Center, Durham, NC USA
    • ,
  • Mette Hammer

      Affiliations

    • Novo Nordisk A/S, Bagsvaerd, Denmark
    • ,
  • Milan Zdravkovic

      Affiliations

    • Novo Nordisk A/S, Bagsvaerd, Denmark
    • ,
  • David Matthews

      Affiliations

    • Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
    • Oxford Biomedical Research Centre, NIHR, Oxford, UK

Received 18 January 2010 ,Accepted 7 April 2010.

References 

  1. Snoek FJ. Barriers to good glycaemic control: the patient's perspective. Int. J. Obes. Relat. Metab. Disord. 2000;24(Suppl. 3):S12–S20
  2. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490–1496
  3. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr. Med. Res. Opin. 2005;21:1477–1483
  4. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br. J. Clin. Pharmacol. 1999;48:643–648
  5. Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diab. Care. 2002;25:458–463
  6. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diab. Care. 2002;25:2238–2243
  7. Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diab. Care. 2009;32:1411–1417
  8. Charpentier G, Fleury F, Dubroca I, Vaur L, Clerson P. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diab. Metab. 2005;31:189–195
  9. Garber A, Henry R, Ratner R, et al. LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481
  10. Bode BW, Hale PM, Hammer M, Testa M, Garber A. Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analog liraglutide or glimepiride. Diabetologia. 2008;51(Suppl. 1):S357
  11. Nauck M, Frid A, Hermansen K, et al. LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diab. Care. 2009;32:84–90
  12. Frid A, Hermansen K, Nauck M, et al. Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data. Diabetologia. 2009;52:S8
  13. Bradley C. Diabetes treatment satisfaction questionnaire. In:  Bradley C editors. Handbook of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers; 1994;p. 111–132
  14. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diab. Care. 1999;22:530–532
  15. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes. Res. 2001;9:102–111
  16. Kolotkin RL, Crosby RD, Williams GR. Assessing weight-related quality of life in obese persons with type 2 diabetes. Diab. Res. Clin. Pract. 2003;61:125–132
  17. Lau CY, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. J. Postgrad. Med. 2004;50:189–193
  18. Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diab. Med. 2005;22:1379–1385

PII: S1751-9918(10)00048-3

doi: 10.1016/j.pcd.2010.04.001

Primary Care Diabetes
Volume 4, Issue 2 , Pages 113-117 , July 2010

Article Tools

* Image Usage & Resolution